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OPTIMAL TUMOR SAMPLING FOR IMMUNOSTAINING OF BIOMARK-
ERS IN BREAST CARCINOMA. Juliana Tolles, Yalai Bai, Maria Baquero, Lyndsay
N. Harris, David L. Rimm, Annette M. Molinaro. Division of Biostatistics, Yale
University School of Public Health, New Haven, CT.
Biomarkers, such as estrogen receptor, are used to determine therapy and prog-
nosis in breast carcinoma. Immunostaining assays of biomarker expression have a
high rate of inaccuracy, for example estimates are as high as 20% for estrogen recep-
tor. Biomarkers have been shown to be heterogeneously expressed in breast tumors
and this heterogeneity may contribute to the inaccuracy of immunostaining assays.
Currently, no evidence-based standards exist for the amount of tumor that must be
sampled in order to correct for biomarker heterogeneity.
The purpose of this study is to determine the optimal number of 20X fields that
are necessary to estimate a representative measurement of expression in a whole tissue
section for selected biomarkers: estrogen receptor (ER), human epidermal growth fac-
tor receptor 2 (HER2), AKT, extracellular signal-regulated kinase (ERK), ribosomal
protein S6 kinase 1 (S6K1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
cytokeratin, and microtubule-associated protein-Tau (MAP-Tau).
Two collections of whole tissue sections of breast carcinoma were immunostained
for biomarkers. Expression was quantified using Automated Quantitative Analysis
(AQUA). Simulated sampling of various numbers of fields (ranging from 1− 35) was
performed for each marker. The optimal number was selected for each marker via
resampling techniques and minimization of prediction error over an independent test
set.
The optimal number of 20X fields varied by marker, ranging between 3−14 fields.
More heterogeneous markers, such as MAP-Tau, required a larger sample of 20X fields
to produce representative measurement. The clinical implication of these findings is
that small core needle breast biopsies may be inadequate to represent whole tumor
biomarker expression for many markers. Also, for biomarkers newly introduced into
clinical use, especially if therapeutic response is dictated by level of expression, the
optimal size of tissue sample must be determined on a marker-by-marker basis.
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Introduction
Biomarkers have become essential for therapeutic decision-making and prognostica-
tion in breast carcinoma. Estrogen Receptor (ER) is the prototypical biomarker for
this cancer; as early as the 1970s, investigations suggested that ER was an indepen-
dent predictor of both breast carcinomas’ response to therapy and the likelihood of
tumor recurrence. In 1974, a workshop convened by the Breast Cancer Task Force
of the National Cancer Institute reviewed the results of 436 treatment trials in 380
patients in an effort to determine whether assays for ER expression in breast car-
cinoma could predict clinical response to hormonal therapies. Hormonal therapies
were not in widespread use at the time and included surgical ablation of estrogen-
producing organs, anti-estrogens, estrogens, glucocorticoids, and androgens [1]. The
committee found that 55-60% of the patients with tumors that tested positive for ER
responded to hormonal therapy (response was defined as a minimum 50% reduction
in size of at least 50% of tumors), whereas only 8% of patients with ER-negative
tumors responded. Shortly afterward, Knight et al. found that ER-negative tumors
were associated with a higher rate of metastasis and lower rate of overall survival in
a cohort of 145 cases [2]. This effect was independent of axillary node status, tumor
size, and tumor location. Knight et al. did not control the effect of adjuvant hor-
monal therapies in this study and, they acknowledged that the differences in survival
between ER-positive and ER-negative subjects might be explained by differences in
therapeutic response.
These findings motivated a series of large randomized, controlled clinical trials of
hormonal therapies, the results of which justified a change in the standard of care to
include ER testing for all breast carcinomas. The first of these trials, the National
Surgical Adjuvant Breast and Bowel Project, began in 1977. It included over 1800
subjects with breast carcinoma at 68 institutions. It found that the addition of ta-
moxifen, an ER antagonist in breast tissue, to the standard chemotherapy regimen
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of L-phenylalanine mustard and 5-fluorouracil improved disease-free survival and sur-
vival for patients with node-positive cancers that expressed ER [3, 4]. ER positivity
was defined as an ER protein level above a threshold of 10 fmol as measured by
ligand-binding assays (LBAs; described further below).
In 1989, a randomized, controlled trial involving over 2600 subjects, demonstrated
that hormonal therapy with tamoxifen increased disease-free survival in patients with
node-negative, ER-positive tumors [5]. Decreases in local recurrence, tumors of the
opposite breast, and treatment failure at metastatic sites all contributed to this result.
The authors concluded that tamoxifen therapy was justified in all subjects who met
inclusion criteria for the study: women under the age of 70, with operable tumors
expressing ER levels ≥ 10 fmol, who met the set of common National Surgical Adju-
vant Breast and Bowel Project inclusion criteria. Stated more generally, the clinical
implication of this study was that ER status should inform the choice of therapy for
all patients with breast carcinoma, regardless of the presence or absence of lymph
nodes positive for carcinoma.
Today, there are two broad classes of hormonal therapy. The first class is selective
estrogen-receptor modulators (SERMs) such as tamoxifen, which, depending on the
tissue type, have either agonistic or antagonistic effects on ER. Although tamoxifen
is the most widely used compound in this class, SERMs include other drugs, such as
fulvestrant. The second class consists of aromatase inhibitors (AIs), such as anastro-
zole, which block conversion of adrenally-produced estrogen precursors into estrogen
[6]. Other methods of hormonal therapy, such as the surgical ablation of estrogen-
producing organs, are not in widespread use. Importantly, a meta-analysis of 78
randomized clinical trials involving over 42,000 patients found that hormonal thera-
pies do not increase survival time for patients with ER-negative tumors, suggesting
that the indiscriminate treatment of all breast carcinomas with hormonal therapy is
inadvisable [7].
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In the last two decades, methods for detecting biomarker expression have benefit-
ted from technological improvements. In 1999, Harvey et al. demonstrated that an
immunohisochemichal assay for ER, which employed a mouse monoclonal antibody
directed against the epitope, predicted disease-free survival with greater accuracy
than ligand-binding assays (LBAs) [8]. Additionally, the immunohistochemical as-
say had several technical advantages over LBAs. LBAs require large quantities of
fresh-frozen tissue, whereas immunohistochemistry can be applied to formalin-fixed
paraffin-imbedded specimens. LBAs also require homogenization of tissue, render-
ing it impossible to determine the relative composition of tumor and benign cells in
the isolate; immunohistochemistry can be performed on histologically intact tissue,
allowing distinguishing morphological features to be left intact. Thus, immunohisto-
chemistry has become the standard assay for measuring breast tumor expression of
ER.
Although ER was the first biomarker used to guide the management of breast
carcinoma, the measurement of several other markers has become part of the standard
of care for this disease. In 1983, Clark et al. found, in a study of 189 women
receiving adjuvant therapy for breast carcinoma, that positive staining of tumors
for progesterone receptor (PR) predicted increased length of disease-free survival.
The analysis demonstrated that this effect was independent of ER expression and of
the type of adjuvant therapy used (regimens including hormonal therapy vs. those
without hormonal therapy) [9]. These results were confirmed by subsequent studies
and, like ER, immunohistochemical assays became the preferred method of detection
for PR [6].
The next pivotal marker for breast carcinoma, HER2, was discovered in the 1990s.
A case-control study conducted by Press et al. of 210 women with node-negative
breast carcinoma found that tumors’ overexpression of the cell surface receptor HER2
predicted likelihood of cancer recurrence [10]. Much like ER, HER2 was first detected
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by immunohistochemistry applied to formalin-fixed sections; however, in this study,
expression levels were also quantified by computer image analysis of immunohisto-
chemically stained tissue sections. Interestingly, a dose-dependent effect was uncov-
ered: subjects with any of level of HER2 overexpression were 3 times as likely to
have a cancer recurrence, whereas those with “high” levels of overexpression were 9.5
times as likely to have a cancer recurrence. Later studies confirmed this finding and
validated in situ hybridization as a alternative technique for detecting HER2 overex-
pression [11]. Subsequent work found that HER2 positivity predicts a lesser likelihood
of response to hormonal therapies, non-anthracycline agents, and non-taxane agents.
Mostly importantly, the presence of HER2 in a breast carcinoma predicts a greater
likelihood of response to trastuzumab, a humanized monoclonal antibody targeted
against HER2. Trastuzumab has been shown to improve survival in both metastatic
and early-stage breast cancer [12, 13].
Taken together, these findings had significant implications for the utility of HER2
measurement in the management of breast carcinoma. An immunohistochemical as-
say for HER2 expression received FDA approval in 1998 and, in 2001, the ASCO/CAP
committee recommended HER2 testing as the standard of care for all newly diagnosed
and metastatic breast carcinoma [14, 15]. The most commonly used clinical algorithm
employs immunohistochemistry to “screen” specimens and reflex fluorescent in situ
hybridization testing of high-scoring cases to confirm results [14].
Commercial assays and academic investigations have moved beyond the use of
individual biomarkers to the development of biomarker “signatures” to inform prog-
nosis and therapeutic decision-making. Oncotype DXTM is 21-gene RT-PCR assay
that measures markers such as Ki67, HER2 family members, and matrix metallopro-
teases in order to stratify ER-positive tumors into “low risk,” “intermediate risk,”
and “high risk” groups with predicted recurrence rates of 7%, 14%, and 31% respec-
tively [16]. In a parallel effort, a recent study of biomarkers in ductal carcinoma in
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situ demonstrated that patients with these precancerous lesions could be stratified
into groups with statistically significant differences in risk for progression to invasive
breast carcinoma. This stratification is based on the expression signature of the fol-
lowing biomarkers: ER, PR, Ki67, p53, p-16, HER2, and cyclooxygenase-2. In that
study, the markers were detected by immunohistochemistry [17].
Many other putative biomarkers of prognosis and therapeutic response are cur-
rently in various stages of pre-clinical investigation [16]. Overexpression of cell cycle
markers, such as cyclin D1 and cyclin E, have been linked to decreased survival times
for patients with breast carcinoma [18, 19, 20]. The H-ras oncogene has been shown
in several studies to be predictive of breast carcinoma progression [21, 22]. Some
evidence suggests that loss of p53 expression in breast carcinoma is predictive of
resistance to hormonal and adjuvant therapies [23, 24]. Overexpression of certain
matrix metalloproteases, believed to be involved in tumor invasion and metastasis,
has been associated with poorer clinical outcomes [25, 26, 27]. Although none of these
markers are currently FDA-approved (or recommended for clinical use by the most
recent ASCO/CAP review of biomarkers in breast cancer [28]), the large number
of promising pre-clinical studies suggests that new markers will become part of the
standard of clinical care in coming years. Of note, the vast majority of these markers
are detected by immunohistochemical methods.
It is therefore concerning that conventional assays for ER and other biomarkers
suffer from lack of objective methods of measurement. Immunohistochemical as-
says have become the standard of care for determining ER and PR status, but the
most recent American Society of Clinical Oncology/College of American Pathologists
(ASCO/CAP) committee review of immunohistochemical assays for breast carcinoma
estimated that “up to 20% of ER and PR determinations worldwide may be inaccu-
rate (false negative or false positive)” [6]. A separate ASCO/CAP committee deter-
mined that approximately the same percentage of HER2 assays for breast carcinoma
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were inaccurate, noting that neither the immunohistochemical assay nor the in situ
hybridization assay for HER2 demonstrated a lower rate of error [14].
National quality assurance audits conducted in the UK and Australia each iden-
tified significant variation in rates of ER- and PR-positivity in laboratories across
those countries [29, 30]. In Canada, where government health services are provided
independently by the provincial governments, it was discovered that, based upon
retesting in a central Ontario laboratory, false negative results had been reported
in approximately 33% of 1,023 samples that underwent ER assays in Newfoundland
laboratories [6]. More than 100 patients in this group died; a subsequent class action
lawsuit was filed against the provincial health service for negligence in ER testing.
In Asian countries – such as the Philippines, Vietnam, and Malaysia – a sig-
nificant rise in the rate of ER-positive breast cancer cases was reported after more
stringent standards for methods of conducting ER assays were introduced [6, 31]. The
ASCO/CAP committee cited all of the above findings to support its development of
a “guideline to improve the accuracy of immunohistochemical estrogen receptor and
progesterone receptor testing in breast cancer and the utility of these receptors as
predictive markers.” The committee hypothesized that misclassifications of ER and
PR status were due to a number of factors, which it grouped into three categories:
pre-analytic variables, thresholds for positivity, and interpretation criteria.
Pre-analytical variables are variations in events that occur prior to immunohis-
tochemical assays, such as length of cold ischemic time, duration of fixation, and
fixative type. In order to reduce the contributions of pre-analytical variables to assay
variability, the committee recommended that pathologists minimize the time from
specimen acquisition to fixation, section specimens at 5 mm intervals to promote
penetration by the fixative solution, use 10% neutral buffered formalin as a fixative,
and limit fixation time to a range between 6− 72 hours. Based on its review of stud-
ies linking patient outcomes to percentage of positive-staining cells, the committee
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lowered the threshold of positivity to a minimum of 1% positive-staining tumor cells
from the previous recommendation of 10% for ER and PR. Lastly, in order to address
variability in interpretation criteria, the ASCO/CAP committee made a variety of
recommendations regarding the use of internal and external controls for immunohis-
tochemical assays, voluntary participation in competency training for pathologists,
and standardization of the reports of assay results.
An earlier committee, convened in 2007, reached similar conclusions about the
sources of inaccuracy in HER2 testing algorithms: it cited pre-analytical variation,
variability in assay reagents, and inadequate pathologist training [14]. The committee
made recommendations for reducing sources of error and variability in the assays for
HER2 that parallel those made by the committee on ER and PR. It also recommended
standardized thresholds for positivity for both immunohistochemical assays (> 30%
positive-staining cells) and in situ hybridization assays for HER2 (> 6 HER2 gene
copies per nucleus or a fluorescent in situ hybridization ratio > 2.2).
However, an additional important possible cause of the high rate of immunohisto-
chemical assay inaccuracy for all biomarkers, given little attention in the ASCO/CAP
reports, is biomarker heterogeneity [32]. Biomarkers are known to be heterogeneously
expressed in breast carcinoma. Biomarker heterogeneity likely stems from numerous
etiologies, including both intrinsic biological causes and variations in specimen han-
dling. Hypotheses for biological sources variation include the inherent DNA instability
in malignant cells, which could generate genetic or epigenetic changes with successive
cell divisions; differences in the tumor microenvironment, such as availability of local
blood supply; and the “cancer stem cell” hypothesis, which holds that a subpopulation
of stem cells produce a variety of tumor cells via a perturbed differentiation process
[33]. Pre-analytical variables, such as slow formalin penetration of thick sections of
tumor tissue, could also produce heterogeneity if some epitopes undergo proteolytic
degradation prior to formalin fixation (Bai et al., in preparation).
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Because of the importance of ER in determining therapy for breast carcinoma,
many investigations have examined intra-tumor heterogeneity of ER expression, and
three of the largest are discussed in detail below. Although each study employed
different expression metrics of heterogeneity and methods of statistical analysis, all
found statistically significant differences in ER expression between different regions
of tumor from the same subject.
The work of Meyer et al., in 1991, represented one the earliest attempts to char-
acterize ER heterogeneity and its potential contribution to the inaccurate assignment
of hormone-receptor status in patients undergoing work-up for breast carcinoma [34].
A cohort of 65 tumors were sampled at 5mm intervals, with a maximum of 8 samples
per tumor. Cytosolic preparations from each sample were processed with a LBA as-
say to determine its ER and PR status. The measured concentrations of ER and PR
were divided into 4 ranges: 2, 10, 50, and 500 fmol/mg respectively (the ranges were
selected arbitrarily, not based on their clinical significance). A tumor was considered
to have heterogeneous expression of the marker if any two samples from the tumor
had scores from non-contiguous ranges. The study found that 24% of tumors were
heterogeneous for ER.
Chung et al. revisited the heterogeneity question using an immunohistochemical
assay for ER, which became the standard of care for detecting ER and PR in the 1990s
[6]. They measured ER expression in samples from 11 patients with breast carcinoma
using quantitative immunofluorescence. For each patient, scores were measured in
different “blocks” of tissue from the same tumor, with each block represented by a
single 1 cm x 1 cm x 5 µm “whole tissue” slide [35]. The differences between scores
of “blocks” from the same tumor was found to be statistically significant (p<0.05)
in 78% of cases. Additionally, the study illustrated heterogeneity between regions
of tumor from the same slide; many slides contained clusters of fields with either
high-intensity or low-intensity staining.
13
Nassar et al. demonstrated heterogeneous intra-tumor expression of ER in a
slightly larger cohort, using both subjective and objective metrics of ER expression.
They constructed TMAs consisting of 44 cases of breast carcinoma, encompassing a
variety of carcinoma subtypes, and five controls of normal breast tissue [36]. Each case
was represented by three 1 mm cores from three distinct tumor foci (total of nine cores
per case). ER expression was quantified both on an ordinal scale of staining intensity
(0 to 3+) and as a percentage of positive-staining cells (0% to 100%) using subjective
visual scoring by light microscopy. These scales were converted into a binary measure
of “ER negative” and “ER positive”: specimens were considered “negative” for ER
if they had a staining intensity of 0 and no more than 10% positive-staining tumor
cells. ER expression was also quantified by Automated Cellular Imaging System
(ACIS; Dako). For the ACIS scoring, scores from the three TMA spots for each
tumor focus were averaged, producing three scores per case.
Biomarker expression was quantified in this investigation using an “intraclass cor-
relation coefficient.” Briefly, the coefficient compares intra-tumor heterogeneity to the
overall variance; a coefficient greater than 0.75 is considered to indicate low hetero-
geneity. The intraclass correlation coefficient for ER was less than 0.75 for all metrics
– staining intensity, percentage of positive-staining cells, and binary score – both
when measured visually and by ACIS.
Biomarkers other than ER have been shown to be heterogeneously expressed in
breast carcinoma. Markers PR, HER2, p53, and MIB-1 have been shown to have
statistically significant differences in intra-tumor expression. Nassar et al., using the
same methods as those described for ER above, demonstrated statistically signifi-
cant heterogeneity of expression for p53, MIB-1, and HER2 in breast carcinoma [36].
Kallioniemi et al. also reported heterogeneity in HER2 overexpression, having iden-
tified subpopulations with different degrees of gene amplification by fluorescent in
situ hybridization [37]. In parallel with their analysis of ER, Meyer et al. demon-
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Figure 1: Heterogeneity of MAP-Tau expression in a whole tissue section of breast
carcinoma. (A) H&E stain (B) Immunofluorescence. Nuclei are labeled with DAPI.
Cytokeratin is labeled with Cy3. MAP-Tau is labeled with Cy5.
strated heterogeneity for PR in breast carcinoma, finding that 20% of tumors were
heterogeneous for the marker [34]. It is likely that many other epitopes are heteroge-
neously expressed in tumors; the heterogeneity of MAP-Tau epitope can be visualized
in immunostained whole tissue sections (Figure 1).
All of the above studies rely upon some form of immunohistochemistry for biomarker
detection, but biomarker heterogeneity has also been demonstrated via the real-
time polymerase chain reaction (RT-PCR) for a variety of biomarkers in a variety
of cancers. Lassman et al. measured heterogeneity of CK20 expression in colorectal
carcinoma using both immunohistochemistry and quantitative RT-PCR [38]. They
first identified tissue with heterogeneous CK20 expression by immunohistochemisti-
cal staining, using visual scoring criteria. They then performed quantitative RT-PCR
on the same tissue, finding an average 3.8-fold difference in CK20 mRNA expression
between cells classified as “weak” staining and those classified as “strong” staining
by immunohistochemistry. Sigalotti et al. demonstrated biomarker heterogeneity for
cancer/testis antigens (MAGE, NYESO, and SSX gene families) in melanoma us-
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ing qualitative RT-PCR [39]. They found different levels of expression for several
biomarkers in single cell isolates cultured from the same melanoma lesion. These
studies confirm that biomarker heterogeneity is demonstrable at the mRNA level and
is not an artifact of immunohistochemical techniques.
A study of several biomarkers – HER2, epidermal growth factor receptor (EGFR),
Bcl-2, p53, and proliferating cell nuclear antigen (PCNA) – conducted by Chhieng
et al., produced results that appear to contradict the above studies [40]. The group
examined 30 breast carcinoma tumors, each a minimum of 1 cm in diameter and 19 of
which had a ductal carcinoma in situ component. It found that immunohistochemical
assays for expression of this group of biomarkers in breast carcinoma exhibited only
“minor regional variations” in EGFR and p53 expression, when those markers were
measured in the invasive ductal carcinoma component, and in PCNA, when it was
measured in ductal carcinoma in situ component.
The precise methods employed in this study are critical to the interpretation of its
findings. For each case, serial 5 µm sections of tumor were immunohistochemically
stained for one marker each. One section was also stained with hematoxylin and eosin
(H&E). The (H&E) section was then divided into four “randomly oriented discrete
regions,” such that each region contained a portion of the invasive cancer. Each
corresponding immunohistochemically stained serial section was divided along these
identical lines. Expression of markers was quantified on by a value on an ordinal
scale (0-4), calculated from the combination of a visual estimate of the percentage of
positive-staining cells and a visual estimate of staining intensity on an ordinal scale.
For the statistical analysis, scores for each of the four regions and whole slides were
then grouped over all 30 cases (although there was no relationship between region
1 case 1 and region 1 from other cases), with distinctions made between regions of
invasive cancer and regions of ductal carcinoma in situ. Whole slide scores for a
single slide were compared to scores from each discrete region by Wilcoxon Signed
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Rank Test. Consistency between the four regional scores was assessed via Spearman
Coefficient. The authors found significant differences between regional and whole
slide scores of EGFR, p53 and PCNA.
Although, Chhieng et al. observed only a few significant differences between the
immunohistochemical scores of tumor regions and whole slides, these results do not
necessarily contradict the findings of previous studies. The authors do not report
the size of the “discrete regions” analyzed, but, given the inclusion criteria minimum
tumor diameter of 1 cm, it is likely that the regions were much larger than the 1
mm-diameter cores analyzed by Nassar et al. in their study of HER2 and p53. This
suggests that there may be some definable minimum size of tumor sample required
to represent biomarker expression in the whole tissue slide.
Furthermore, Chhieng et al. did not use the objective, continuous scoring for
biomarker expression, such as the AQUA system employed by Chung et al.; an ordinal
scoring scale has less statistical power to detect small differences in expression levels.
Taken together with the previously described investigations of biomarker heterogene-
ity, this study suggests that there is a need to define a minimum size of representative
tumor section using an objective, continuous scoring system for immunohistochemical
assays.
Chhieng et al. also examined differences in the percentage of positive-staining
cells between regions of invasive carcinoma on a case-by-case basis. Differences in
the degree of heterogeneity were detected: up to 66% absolute difference in percent-
age staining for HER2 (membranous), 50% for HER2 (cytoplasmic), 50% for EGFR
(membranous), 53% for EGFR (cytoplasmic), 113% for Bcl-2, 66% for p53, 62% and
for PCNA. This suggests that different markers may have different degrees of hetero-
geneity and that any investigation seeking to define minimum sampling should do so
on a marker-by-marker basis.
Given the overwhelming evidence of biomarker heterogeneity in breast carcinoma,
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it is plausible that insufficient tumor sampling in the clinical setting may lead to mis-
classification of biomarker status and inappropriate treatment of patients. Despite
the extensive description of the phenomenon of biomarker heterogeneity in breast
carcinoma, no evidence-based standards have been developed for the size of tissue
sample necessary to correct for heterogeneity in assays of biomarker status. Core
needle biopsies, which represent a very small percentage of the entire tumor tissue,
are used for biomarker testing in many clinical pathology laboratories. It is possible
that these small samples are inadequate in some fraction of cases. Although, the 2010
ASCO/CAP recommended that “large, preferably multiple core biopsies of tumor are
preferred for testing if they are representative of the tumor (grade and type) at resec-
tion” [6], it gave no additional specific guidance regarding the minimum acceptable
sample size. The committee could not offer a more precise recommendation because,
to our knowledge, no prior investigations point to a precise standard for the mini-
mum number of cores or sections of resection tissue required to account for biomarker
heterogeneity in determining the biomarker expression of breast carcinoma tumors.
Statement of Purpose and Specific Aims
The goal of this study is to estimate the degree of sampling required to make an
accurate assessment of biomarker status for the following 7 biomarkers in breast car-
cinoma:estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2),
AKT, extracellular signal-regulated kinase (ERK), ribosomal protein S6 kinase 1
(S6K1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), cytokeratin, and microtubule-
associated protein-Tau (MAP-Tau). We expected these markers, based on knowledge
of their biological roles, to represent a range from relatively homogeneous to rela-
tively heterogeneous. GAPDH, a ubiquitously expressed “housekeeping” gene, and
cytokeratin, a structural protein present in all epithelial cells, we predicted to be ex-
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pressed relatively homogeneously within tumors. We expected ER and microtubule-
associated protein-Tau (MAP-Tau), based on previous studies and visualization with
immunofluorescence, to be more heterogeneous. The specific hypothesis is that mark-
ers with greater heterogeneity will require a larger number of sampled fields to produce
a representative measurement.
Specific Aims:
1. Quantify the degree of heterogeneity for each marker using mixed-effects mod-
eling.
2. Simulate sampling different amounts of tumor in order to determine the optimal
number of 20X fields required to give a measurement of biomarker expression
representative of the entire tissue sample.
Methods
Author Contributions
JT performed the statistical analyses detailed in Methods: Statistical Methods.
YB and MB carried out the preparation of tissue, AQUA assays, and collection of
data. LNH was responsible for tissue acquisition from TAX 307 cohort. DLM con-
ceived of the study and participated in its design. AMM designed the statistical
analyses and participated in the study design.
Cohorts
The first collection of subjects consisted of 14 tumor resection specimens from patients
who underwent surgery at Yale University/New Haven Hospital between 2001 to 2005.
Whole tissue sections of formalin-fixed, paraffin-embedded primary invasive breast
cancer tumors were obtained from the archives of the Pathology Department of Yale
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University. All the patients were diagnosed with infiltrating ductal carcinoma of the
breast. None received chemotherapy or radiation prior to resection. The study was
approved by the institutional review board for Yale University.
The second collection of subjects was a cohort (n = 122) from TAX 307, a prospec-
tively collected, independent phase III clinical trial comparing docetaxel-doxorubicin-
cyclophosphamide (TAC) versus 5-fluorouracil- doxorubicin-cyclophosphamide (FAC).
Patients were enrolled between January 1, 1998 and December 31, 1999, with a to-
tal of 484 patients randomized to receive either FAC (75/50/500 mg/m2) or TAC
(500/50/500 mg/m2) as first line chemotherapy for metastatic breast cancer. All
patients provided clinical consent prior to enrollment. Specimens and associated clin-
ical information were collected under the guidelines and approval of the Dana Farber
Human Investigation Committee under protocol #8219 to L.H.
Antibodies and Immunohistochemistry
The TAX 307 clinical trial cohort consisted of 122 whole section slides. Five µm
tissue sections from formalin-fixed paraffin-embedded tumor blocks were mounted on
aminosilane glass slides (plus slides) and heated. Slides were immunostained using
MAP-Tau monoclonal antibody which recognizes all human MAP-Tau isoforms inde-
pendent of phosphorylation status (1:750; mouse monoclonal, clone 2B2.100/T1029,
US Biological, Swampscott, MA). Slides were divided into six individual batches,
each including one Breast Cancer Cell Line Control TMA slide. TAX 307 slides were
incubated for 24 hours at 60◦C. Slides were deparaffinized by oven incubation at 60◦C
for 20 minutes, followed by two 20 minute incubations in xylene. After slides were
washed twice in 100% ethanol, once in 70% ethanol, and rehydrated with tap water,
antigen retrieval by pressure cooking was performed in 6.5 mM sodium citrate buffer
(pH 6.0) for 10 minutes. Endogenous peroxidase activity was quenched in methanol
and 3% hydrogen peroxide for 30 minutes followed by rinsing in tap water and place-
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ment in 1X trisethanolamine-buffered saline (TBS; pH 8.0). Non-specific binding was
reduced using a 30 minute preincubation in 0.3% bovine serum albumin (BSA) in
0.1M tris-buffered saline (TBS, pH=8) with 0.05% Tween (TBS-T).
Slides were prepared for 4◦C overnight incubation (12 hours) by adding a cocktail
of MAP-Tau primary antibody (1:750) plus a wide-spectrum rabbit anti-cow cytok-
eratin antibody (Z0622; Dako, Carpinteria, CA) diluted 1:100 in BSA/1X TBS-T.
Following overnight incubation, slides were washed twice in 1X TBS with 0.05%
Tween for 10 minutes and once in 1X TBS. Secondary antibody was then applied
for 1 hour at room temperature. Goat antirabbit Alexa 488 (Molecular Probes, Eu-
gene OR) was diluted 1:100 in horseradish peroxidase-conjugated EnVision antimouse
secondary antibody (Dako). Following incubation with secondary antibodies, slides
were washed twice (10minutes, then 5minutes) in 1xTBS-T and once (5 minutes)
in 1xTBS. Cyanine-5 (Cy5) directly conjugated to tyramide (FP1117, Perkin-Elmer,
Boston MA), diluted 1:50 in amplification diluent (Perkin-Elmer) was used as the
fluorescent chromagen for target detection and was added to all slides for 10 minutes
at room temperature. Two final washes (10minutes, then 5minutes) in 1X TBS-T and
one 5 minute wash in 1X TBS were performed. Slides were stained for double-stranded
DNA using Prolong Gold mounting medium with anti-fade reagent 4’,6-diamidino-
2-phenylindole (”DAPI”, Molecular Probes, Eugene OR). Normal breast epithelium
served as internal positive controls while omission of the primary antibody served as
the negative control for each immunostaining event.
For all epitopes other than MAP-Tau, immunostaining was performed on sets of
serial slides from the first collection of subjects (n=14) and the following protocol
was used for MAP-Tau. Whole tissue sections were incubated at 60◦C for 20 minutes
before being deparaffinized with xylene, rehydrated, endogenous peroxidase blocked,
and antigen-retrieved by pressure cooking for 15 min in citrate buffer (pH = 6).
Slides were pre-incubated with 0.3% bovine serum albumin in 0.1 mol/L TBS (pH =
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Protein Species Clone Dilutions Supplier
ER Mouse mAb 1D5 1:50 Dako
HER2 Rabbit pAb A0485 1:2000 Dako
AKT Rabbit mAb 11E7 1:1000 CST
ERK1/2 Mouse mAb L34F12 1:1000 CST
S6K1 Rabbit mAb 49D7 1:450 CST
GAPDH Rabbit mAb 14C10 1:500 CST
Table 1: Antibodies, epitopes, sources and dilutions
8) for 30 min at room temperature. The procedure for pAKT staining was a follows:
slides were incubated with a cocktail of ERK1/2 antibody diluted at 1:1000 (Mouse
monoclonal, clone L34F12; Cell Signaling Technology, Danvers, MA) and a wide-
spectrum rabbit anti-cow cytokeratin antibody (Z0622; Dako Corp, Carpinteria, CA),
diluted 1:100 in bovine serum albumin/TBS overnight at 4◦C. This was followed by a
1-hour incubation at room temperature with Alexa 546-conjugated goat anti-rabbit
secondary antibody (A11010; Molecular Probes, Eugene, OR) diluted 1:100 in mouse
EnVision reagent (K4001, Dako Corp, Carpinteria, CA). Cyanine 5 (Cy5) directly
conjugated to tyramide (FP1117; Perkin-Elmer, Boston, MA) at a 1:50 dilution was
used as the fluorescent chromogen for pAKT detection. Prolong mounting medium
(Prolong Gold, P36931; Molecular Probes, Eugene, OR) containing 4’,6-diamidino-
2-phenylindole was used to identify tissue nuclei. Immunostaining for all remaining
epitopes was done in a similar manner with antibodies as follows outlined in Table 1.
Image Capture and Analysis
Automated Quantitative Analysis (AQUA) allows exact measurement of protein con-
centration within subcellular compartments, as described in detail elsewhere [41]. In
brief, a series of high-resolution monochromatic images were captured by the PM-2000
microscope (HistoRx). For whole tissue sections, multiple regions of interest (ROIs)
containing invasive tumor were circled on the AQUA system screen based on the
low-resolution cytokeratin (cytoplasm) image of the immunohistochemically stained
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slide taken with the AQUA system. The selected ROIs were automatically overlaid
with a grid by the image capturing program and each 20X field of view (FOV) was
defined automatically.
For each FOV, in-focus and out-of-focus images were obtained using the signal
from the 4’,6-diamidino-2-phenylindole, cytokeratin-Alexa 546 and target protein-Cy5
channel. Target protein antigenicity was measured using a channel with emission
maxima above 620 nm, in order to minimize tissue autofluorescence. Tumor was
distinguished from stromal and non-stromal elements by creating an epithelial tumor
“mask” from the cytokeratin signal. The binary mask – in which each pixel is either
“on” or “off” – is created on the basis of an intensity threshold set by visual inspection
of FOVs.
The AQUA score of the target protein in each subcellular compartment was cal-
culated by dividing the target protein compartment pixel intensities by the area of
the compartment within which they were measured. AQUA scores were normalized
to the exposure time and bit depth at which the images were captured; thus, scores
collected at different exposure times are directly comparable.
Statistical Methods
Normalization
Similar to other methods for quantifying fluorescent signals, AQUA scores are subject
to some variation between analyses performed at different times. Potential sources of
variation, such as buffer lot and microscope bulb hours, are numerous and impossible
to completely eliminate. We therefore normalized AQUA scores between analyses
performed at different times.
All epitopes with the exception of MAP-Tau and ER were processed in a single
AQUA run and therefore did not require normalization. MAP-Tau and ER were pro-
cessed in combination with standardized index TMAs, which consisted of a sample of
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tissue from breast carcinoma cases and cell lines. To normalize scores of the experi-
mental subjects for MAP-Tau and ER, quantile normalization was first performed on
the index TMA [42]. The normalization was performed separately for each epitope.
The algorithm for quantile normalization is as follows:
1. Build a p x n matrix X with observations p in rows and different AQUA pro-
cessing runs of the index TMA n in columns.
2. Sort values in descending order within array X columns to create Xsort.
3. Replace each value in rows of Xsort with the mean value of Xsort.
4. Get XNormalized by rearranging each column in Xsort to have the same ordering
as the original X.
The quantile normalization algorithm assumes that the two sets of data to be
normalized are identically distributed [42]. Given that the un-normalized data in this
case consists of two repeated measurements of an identical index TMA, processed
under the same protocol, the assumption holds true for this data set.
Next, smoothing splines Sj were fit to describe the transformation between each
column j in the original matrix of index TMA scores and the corresponding column
in the normalized matrix:
Sj(Xj) = XNormalizedj
Smoothing splines are functions defined by locally fit third-degree polynomials, which
are constrained by a smoothing parameter to produce a continuous function over the
range of the whole data set [43].
A single “baseline” column i was selected from the matrix X. In the last step of
normalization, the spline transformation from each index matrix column Sj (j 6= i)
was applied to the scores of cases processed with that array, followed by the applica-
tion of the inverse of the spline function for the baseline array. This transformed the
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scores to the scale of the “baseline” run. Thus, for the matrix of cases Xc, the final
transformation applied was:
S−1i (Sj(Xcj)) for j 6= i
This normalization method has been validated on several independent cohorts for
breast carcinoma (Tolles et al., in preparation). It is one of many possible normal-
ization algorithms that could be employed for our data.
Linear Mixed-Effects Modeling
A linear mixed-effects model is a type of linear model that incorporates both fixed
effects, which are associated with a population or predictable levels of experimental
factors, and random effects, which are associated random variation among individuals
within the population [44]. Mixed effects models are used to characterize relation-
ships between a response variable (AQUA score) and covariates in the data grouped
according to one or more classification factors. In this study the classification factors
are the subject and ROI within a given subject. Parameter coefficients are calculated
by restricted maximum likelihood estimation.
Linear mixed-effects modeling makes several assumptions about the underlying
structure of the data. First, it assumes that within-group errors are independent,
identically normally distributed and independent of the random effects. Second, it as-
sumes that the random effects are normally distributed and independent for different
groups. These assumptions were verified for our data by the use of quantile-quantile
plots of both the residuals and the random effects. A quantile-quantile plot plots
the quantiles of the observed data against the predicted quantiles of a normal distri-
bution. If the resulting plot is linear, the observed data are judged to be normally
distributed.
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Mixed Effects models were fit for each epitope of interest. The form of the model
was:
yijk = β + bi + bj + 
where yijk is the AQUA Score of the i
th subject, in the jth ROI, at the kth FOV. β
is the intercept term and  is the residual. The model assumes bi ∼ N(0, σ21) and
bj ∼ N(0, σ22). The interpretation of the model is that σ21 represents the variance
between AQUA scores of individual subjects and that σ22 represents variance between
AQUA scores of regions within a sample from a subject.
In order to quantify the degree of heterogeneity with a metric that would be com-
parable across epitopes, we calculated the coefficient of variation for each epitope.
Generally the coefficient of variation is defined to be the ratio of the standard de-
viation of a distribution to the mean of that distribution. Thus, the coefficient of
variation for the study was calculated as σ̂2
β0
.
The R Language and Environment for Statistical Computing and NLME package
were used for all computations [44].
Sampling Simulation: Model Selection and Cross-Validation
Due to the inherent differences in the two cohorts, the analyses of the biomarkers
differed slightly. However, in both, to choose the optimal number of fields (i.e. model
selection) and estimate the corresponding prediction error we used two layers of re-
sampling [45, 46]. The first, or outer, layer was for estimating prediction error and
the second, or inner, layer for model selection (see Figure 2).
For the MAP-Tau cohort, we employed 10-fold cross-validation for the first layer
and Monte Carlo cross-validation for the second [47]. In the first layer the cohort was
divided equally into ten groups. For each iteration, one of the groups served as an
independent test set for calculation of prediction error while the other nine groups (i.e.
90% of the subjects) constituted the training set. In the second layer, this training set
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was subdivided into a learning set (90% of training set) and an evaluation set (10% of
training set), for the purposes of selecting the optimal number of 20X FOVs. For each
of the total 10 training sets, the learning and evaluation sets were both reconstituted
1000 times. A linear regression model was fit to the subjects in the learning set.
The corresponding independent variable was the average AQUA Score of a subset of
20X FOVs sampled from each whole tissue slide, and the dependent variable was the
overall average score for all FOVs on that slide. A separate regression was calculated
for each potential number of FOVs (1 − 35). Using the coefficients estimated from
the regression model developed on the learning set, a predicted score was calculated
for each subject in the evaluation set for every number of FOVs. The prediction error
(PE) was calculated as follows for each number of FOVs and then averaged over the
1000 evaluation sets:
PE =
1
N
N∑
i=1
(xˆi − x¯i)2, (1)
where N = # of subjects, x¯i =
1
K
∑K
j=1 xj, and K = # of fields in subject i. The first
local minimum of the average prediction error was recorded.
Lastly, the mean PE for the independent test sets was calculated by averaging the
PE over the 10 independent test sets for each potential number of FOVs (1−35). The
average first local minimum and standard error for the test set PE was recorded. In
accordance with rules of parsimonious model selection [48], if there existed a model
(here, a model is the number of FOVs) with mean PE within one standard error of
that of the minimum model, the smaller model was selected as optimal. The entire
process was repeated 100 times and the result averaged to produce a stabile estimate
of the optimal number of FOVs. The standard deviation over the 100 repetitions was
also calculated.
For all epitopes of interest other than MAP-Tau, the small number of FOVs mea-
sured for each subject required an alternative to the method of direct sampling used
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Figure 2: (1) Division of Cohort into Test Set and Training Set. Repeated 10 times.
(2) Division of training set into learning set and evaluation set. Repeated 1000 times.
(3) Fitting of linear regression over learning set. Performed for sample sizes of 1 −
35 FOVs. Calculation of average prediction error over evaluation set. Red arrow
indicates first local minimum. (4) Calculation of average prediction error over the
test set. Gray arrow indicates over local minimum over 10 training sets. Black arrow
indicates smallest value within one standard error of average first local minimum.
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for MAP-Tau. Direct sampling would have introduced bias into the analysis, be-
cause of the relatively small number of FOVs available for each subject. For example,
given a subject with only 10 FOVs, a sample of size of 10 would have consisted of
all available FOVs from that subject’s whole tissue section. Therefore, the average
and standard deviation from each subject was used to describe a normal distribution.
Then, randomly generated observations from that normal distribution were sampled
as above.
For epitopes other than MAP-Tau, in the first layer, leave-one-out cross-validation
was used in place of 10-fold cross-validation. That is, in each iteration of the cross-
validation, the test set consisted of one subject and the remaining subjects constituted
the training set. Again, in the second layer, the training set was subdivided into
learning and evaluation sets. However due to the small sample sizes, instead of Monte
Carlo Cross-Validation, we employed bootstrap sampling, in which a training set of
size n was sampled with replacement to create a learning set of size n. Subjects not
selected for the learning set made up the evaluation set. A linear model was used
in a similar manner as for MAP-Tau and an optimal number of FOVs was selected
by averaging the prediction error in the evaluation set over 1000 iterations of the
training set splitting procedure. Test set error was calculated in the same manner as
for MAP-Tau and the one-standard-error parsimony rule again applied to select the
final “optimal” number of FOVs. As in the MAP-Tau cohort, the entire process was
repeated 100 times and the average and standard deviation calculated.
In order to test the validity of the simulated sampling method used for these
epitopes, an additional analysis was performed on the MAP-Tau data. For each of
the 122 subjects, a subset of 20 FOVs was randomly sampled from all FOVs available.
Randomly generated values from a normal distribution described by the mean and
variance of the 20 FOV subset was then used for selection of optimal number of FOVs
and calculation of prediction error was then performed.
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For all epitopes, to assess how close the predicted value was to the overall average
AQUA score, we computed the absolute distance of the two values divided by the
standard deviation of AQUA scores for each person as:
1
N
N∑
i=1
|xˆi − x¯i|
sxi
, (2)
where N , x¯i, and K are defined in Equation 1 and sxi =
1
K
∑K
j=1(xj− x¯i)2. This value
was then averaged over the layers of cross-validation resulting in an average absolute
standardized score. The R Language and Environment for Statistical Computing was
used for all computations.
Results
Mixed-Effects Analysis of Intra-tumor Heterogeneity
We calculated an average intra-tumor coefficient of variation by epitope via a mixed-
effects model fit to the AQUA scores from the 20X FOVs. Results appear in Figure 3
and are expressed as percentages with 95% confidence intervals. Overlapping intervals
indicate that there is no significant difference between the coefficients of variation.
Information about the location of FOVs in ROIs on the whole tissue slide was not
collected for MAP-Tau and cytokeratin proteins; it therefore was not possible to
calculate a coefficient of variation for these epitopes. The only significant differences
detected were between the coefficients for ERK and ER. Of note, the “housekeeping”
protein GAPDH, which we expected to show relatively homogeneous expression, has
a coefficient of variation that is not statistically significantly different from that of
ER or HER2.
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Figure 3: Coefficient of Variation (%) by epitope with 95% confidence intervals.
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Cross-Validated Optimal Number of FOVs
For each epitope of interest, we simulated taking 1−35 FOVs for a subset of subjects
(the learning set). We then used the average AQUA Score of the sampled FOVs to
develop a linear model. The model was used to predict scores for a distinct group
of subjects, the test set, from which the same number of FOVs were sampled. Next,
we calculated the PE, which is the average squared error from each set of predictions
over the test set. We repeated this simulation with different learning and test sets,
as described in the methods. Lastly, we located the average first local minimum of
the PE and recorded the smallest number of FOVs within one standard error of this
minimum. The result appears in the first column of Table 2. Also shown are the
standard error of the estimate and the corresponding average absolute standardized
score (Equation 2).
The optimal number of fields for epitopes ranged from 3−14. Standard error of the
estimate ranged from 1.1−4.2, demonstrating that the estimates generated were sta-
ble. There are significant differences in the optimal number of FOVs between some
of the epitopes. These differences roughly correlate with the results of the mixed-
effects analysis of heterogeneity: the coefficients of variation for ER, HER2, AKT,
S6K1 were not found to be significantly different and, correspondingly, the optimal
FOV results for these epitopes are similar. Cytokeratin and MAP-Tau, for which it
was not possible to calculate coefficients of variation, have optimal numbers of FOVs
of 3 and 14 respectively. Given the qualitative heterogeneity of MAP-Tau on visual
analysis and contrastingly ubiquitous expression of cytokeratin in breast carcinoma,
these results support the hypothesis that markers with greater heterogeneity have a
larger optimal number of FOVs. However, the correspondence between biomarker
heterogeneity and optimal number of FOVs was not perfect: ER and ERK had sig-
nificantly different coefficients of variation and yet had optimal number of FOVs of 8
and 6 respectively. The average absolute standardized score at the optimal number of
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Marker Optimal
Number of
20X FOVs
SE of Optimal
Number (FOVs)
Average Absolute
Standardized Score
(Equation 2)
ER 8 3.4 .31
HER2 5 3.0 .56
AKT 4 1.5 .65
ERK 6 2.5 .31
S6K1 6 3.4 .21
GAPDH 12 4.1 .24
Cytokeratin 3 4.3 .41
MAP-Tau 14 4.2 .60
MAP-Tau
(direct sam-
pling)
14 4.2 .55
Table 2: Optimal Number of Fields by Epitope with PE
fields is reported as an average distance in terms of a subjects’ AQUA score standard
deviation. For example, for ER, a subject’s predicted score, as calculated from the
optimal number of FOVs, will, on average, differ from the subject’s “true” score by
.31 standard deviations. The average absolute distance at the optimal number of
FOVs varies slightly between epitopes but remains below one standard deviation for
all but one epitope.
As described in the methods, due to the small sample size and number of FOVs, the
biomarkers besides MAP-Tau were imputed by simulating from a normal distribution
based on the observed mean and standard deviation of the each individual biomarkers.
To test the validity of this imputation, we performed the simulation with MAP-Tau
and the results were almost identical to the results when we employed direct sampling
of observed data (Table 2).
Discussion
We investigated biomarker heterogeneity and the optimal number of 20X FOVs re-
quired for accurate immunostaining assessment of biomarker expression in breast car-
cinoma. Our mixed-effects analysis showed that, of the 7 biomarkers we examined,
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there were significant differences in heterogeneity, as quantified by the intra-tumor
coefficient of variation. The optimal number of 20X FOVs, as determined by the
cross-validated average prediction error, varied by epitope from 3 (for cytokeratin) to
14 (for MAP-Tau).
The clinical significance of our findings is two-fold. First, they demonstrate that
very small core needle biopsies may be inadequate for use in diagnostic immunostains
because they may not contain enough 20X FOVs to account for biomarker hetero-
geneity. Second, they suggest that the optimal tissue sampling algorithm required
to account for biomarker heterogeneity must be determined individually for each
biomarker introduced into clinical use.
The results for the optimal number of FOVs by biomarker trended with the results
of the mixed-effects analysis of heterogeneity. The markers S6K1, ERK, AKT, and
HER2 had similar optimal FOV sample sizes and a correspondingly large overlap in
the 95% confidence intervals for their coefficients of variation. ER, which had the
highest measured coefficient of heterogeneity, had a relatively large optimal sample
size. Although it was not possible to calculate a coefficient of variation for MAP-Tau,
its large optimal FOV sample size is consistent with the qualitative heterogeneity ob-
served in immunostains. The similarity of the optimal number of FOVs between ER
and ERK, despite significant differences in their coefficients of correlation, demon-
strates imperfect correspondence between mixed-effects modeling of heterogeneity
and the optimal number of FOVs. This suggests that optimal sampling must be em-
pirically calculated for each marker rather than predicted from statistical models of
marker heterogeneity.
The differences between the optimal number of FOVs for the biomarkers we tested
suggests that there exists no single, optimal sampling algorithm for all biomarkers
in breast carcinoma. Instead, the optimal number must be determined on a marker-
by-marker basis. Biomarkers that are known to be more heterogeneous, such as
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MAP-Tau, are likely to require more FOVs; however, for the reasons stated above,
precise sampling algorithms must be empirically determined.
This study has several limitations. The the most important limitation is that we
used the average AQUA score over all FOVs in a whole tissue slide to model the “true”
representative score for each tumor when calculating prediction error. Similarly, we
used FOVs from one whole tissue slide per subject to calculate the coefficient of
variation for each biomarker. The variation within a single whole tissue slide may be
far less than the variation between histologic “blocks” (1 cm3 sections) from different
regions of tumor. As described above, Chung et al. found statistically significant
differences between AQUA scores from different blocks of tumor [35]. Different blocks
are more likely to encompass various tumor micro-environments and different tumor
cell subpopulations. Consequently both the coefficient of variation and the optimal
number of FOVs reported in this study may underestimate variation in the tumor as
whole.
Our results may be conservatively interpreted as the minimum number of FOVs
required for clinical use. In clinical practice, immunostaining for biomarkers is some-
times performed on core needle biopsies, which are much smaller than whole tissue
sections. Our findings offer guidance regarding the size of core needle biopsy sample
required to represent biomarker expression in a single whole tissue section. Addi-
tional studies, using multiple blocks from the same tumor, will be required to draw
inferences about the optimal number of FOVs required to represent the tumor as a
whole.
A second limitation of this study is the relatively small size of the cohort on which
most of the biomarkers were measured. The mixed-effects analysis only detected a
significant difference between coefficients of variation for two of the epitopes exam-
ined: ER and ERK. It is possible that the study was underpowered to detect small
differences in coefficients of variation between epitopes; a larger cohort size may have
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produced more stable estimates of the coefficients of variation, allowing for detection
of small, but statistically significant differences. In addition – based on what is known
about distinct biological roles of GAPDH versus ER and HER2 – we would not have
predicted that we would find no significant difference between the coefficients of vari-
ation for these markers. It is possible that, in this small cohort, the cases selected
had relatively homogeneous expression of HER2 and ER that was not representative
of the typical level of intra-tumor heterogeneity in breast carcinomas.
Another consequence of the small cohort size was that we were required to use
imputed values in the cross-validation analysis. For all biomarkers other than MAP-
Tau, in order to avoid introducing bias, we simulated sampling FOVs from a normal
distribution described by the measured mean and variation of observed FOVs. How-
ever, the validity of this method is supported by our dual analysis of MAP-Tau, which
was measured on a large cohort (n=122), with a large number of FOVs measured per
subject. When the MAP-Tau data was analyzed by both direct sampling and simu-
lation, the results for the optimal number of fields and standard error of the estimate
were identical. This is strong evidence that neither the point estimate for optimal
number of FOVs for epitopes other than MAP-Tau nor the stability of this estimate
were affected by the small cohort size.
The third limitation is that AQUA is not currently used in many clinical laborato-
ries. AQUA employs fluorescence for visualization and optimal quantification rather
than the diaminobenzidine (DAB) stain used in most conventional labs. However, the
underlying immunohistochemistry technique and biology are the same, so the results
should be generalizable to any method of visualization. For several reasons, AQUA
is superior to DAB for the purposes of this study. In validation studies, AQUA has
demonstrated superior reproducibility and predictive power (of clinical outcomes)
when compared to pathologist-based scoring systems of DAB stains [41]. AQUA
measures a much greater dynamic range of scores than DAB, allowing it differentiate
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between levels of biomarker expression that might be indistinguishable with DAB
staining [49]. AQUA also allows for more powerful statistical analysis: it measures
biomarker expression on a continuous scale, which has greater statistical power to de-
tect differences than the ordinal scale employed in pathologist-based scoring systems
of DAB stains.
This pilot study offers guidance regarding the size of tissue sample that is required
to account for heterogeneity in the specific biomarkers studied. More broadly, it sug-
gests that further investigations are necessary in order to describe optimal sampling
for other biomarkers in pre-clinical or clinical use. The implication for clinical prac-
tice is that number of fields assessed is a critical parameter for companion diagnostic
tests and should be optimized prior to introduction of new biomarker assays. While
this is a study of breast carcinoma tumors, the implications of these findings extend
to biomarkers used in other types of tissue.
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